## Kyu-Man Han

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3344876/publications.pdf

Version: 2024-02-01

185	5,188	36	61
papers	citations	h-index	g-index
190	190	190	7152 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric study. Comprehensive Psychiatry, 2008, 49, 218-223.	3.1	344
2	Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam Medical Journal, 2018, 54, 101.	0.9	181
3	Current Clinical Applications of Diffusion-Tensor Imaging in Neurological Disorders. Journal of		

71 70 68 68
68
68
68

#	Article	IF	CITATIONS
37	Imaging genetics studies on monoaminergic genes in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 311-319.	4.8	37
38	Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. Journal of Psychiatric Research, 2017, 84, 292-300.	3.1	37
39	Interactive effects of genetic polymorphisms and childhood adversity on brain morphologic changes in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 4-13.	4.8	37
40	Neural substrates for late-life depression: A selective review of structural neuroimaging studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110010.	4.8	37
41	Study design and methods of the Ansan Geriatric Study (AGE study). BMC Neurology, 2009, 9, 10.	1.8	35
42	Local gyrification index in patients with major depressive disorder and its association with tryptophan hydroxylaseâ€2 ( <scp><i>TPH2</i></scp> ) polymorphism. Human Brain Mapping, 2017, 38, 1299-1310.	3.6	35
43	The effects of 5-HTTLPR and BDNF Val66Met polymorphisms on neurostructural changes in major depressive disorder. Psychiatry Research - Neuroimaging, 2018, 273, 25-34.	1.8	35
44	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clinical Psychopharmacology and Neuroscience, 2018, 16, 469-480.	2.0	35
45	Vilazodone for the Treatment of Depression: An Update. Chonnam Medical Journal, 2016, 52, 91.	0.9	34
46	Tinnitus, depression, and suicidal ideation in adults: A nationally representative general population sample. Journal of Psychiatric Research, 2018, 98, 124-132.	3.1	34
47	Normative data and psychometric properties of the Patient Health Questionnaire-9 in a nationally representative Korean population. BMC Psychiatry, 2020, 20, 194.	2.6	33
48	Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis. Journal of Psychiatric Research, 2020, 125, 164-176.	3.1	33
49	Chronic medical conditions and metabolic syndrome as risk factors for incidence of major depressive disorder: A longitudinal study based on 4.7 million adults in South Korea. Journal of Affective Disorders, 2019, 257, 486-494.	4.1	31
50	Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study. Journal of Psychiatric Research, 2015, 66-67, 84-94.	3.1	30
51	Usefulness of the Patient Health Questionnaire-9 for Korean Medical Students. Academic Psychiatry, 2014, 38, 661-667.	0.9	28
52	Assessing reporting quality of randomized controlled trial abstracts in psychiatry: Adherence to CONSORT for abstracts: A systematic review. PLoS ONE, 2017, 12, e0187807.	2.5	28
53	Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1219-1223.	4.8	27
54	The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. Journal of Psychiatric Research, 2014, 56, 72-81.	3.1	27

#	Article	IF	CITATIONS
55	Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder. Brain, Behavior, and Immunity, 2020, 87, 852-859.	4.1	27
56	Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action. Psychiatry Investigation, 2015, 12, 155.	1.6	26
57	Emotional labor and depressive mood in service and sales workers: Interactions with gender and job autonomy. Psychiatry Research, 2018, 267, 490-498.	3.3	25
58	Validation of the Korean version of the Generalized Anxiety Disorder 7 selfâ€rating Scale. Asia-Pacific Psychiatry, 2020, , e12421.	2.2	25
59	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry, 2016, 16, 106.	2.6	24
60	ARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder. Genes, 2019, 10, 907.	2.4	23
61	Standardization of the Korean Version of the Posttraumatic Embitterment Disorder Self-Rating Scale. Psychiatry Investigation, 2012, 9, 368.	1.6	23
62	Outpatient Follow-Up Visit after Hospital Discharge Lowers Risk of Rehospitalization in Patients with Schizophrenia: A Nationwide Population-Based Study. Psychiatry Investigation, 2015, 12, 425.	1.6	23
63	Alterations in functional brain networks in depressed patients with a suicide attempt history. Neuropsychopharmacology, 2020, 45, 964-974.	5.4	22
64	Venlafaxine versus Mirtazapine in the??Treatment of Undifferentiated Somatoform Disorder. Clinical Drug Investigation, 2008, 28, 251-261.	2.2	21
65	Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants. Behavioural Brain Research, 2015, 292, 116-124.	2.2	21
66	Plasma ATG5 is increased in Alzheimer's disease. Scientific Reports, 2019, 9, 4741.	<b>3.</b> 3	21
67	Social support moderates association between posttraumatic growth and trauma-related psychopathologies among victims of the Sewol Ferry Disaster. Psychiatry Research, 2019, 272, 507-514.	<b>3.</b> 3	21
68	Impact of tryptophan hydroxylase 2 G-703T polymorphism on anger-related personality traits and orbitofrontal cortex. Behavioural Brain Research, 2012, 231, 105-110.	2.2	20
69	Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study. Journal of Psychiatric Research, 2014, 49, 75-82.	3.1	20
70	Perspectives on the Happiness of Community-Dwelling Elderly in Korea. Psychiatry Investigation, 2016, 13, 50.	1.6	20
71	Association between Serotonin Transporter-Linked Polymorphic Region and Escitalopram Antidepressant Treatment Response in Korean Patients with Major Depressive Disorder. Neuropsychobiology, 2012, 66, 221-229.	1.9	19
72	Mental health service use in adults with suicidal ideation within a nationally representative sample of the Korean population. Journal of Affective Disorders, 2016, 193, 339-347.	4.1	19

#	Article	IF	Citations
73	Interaction effects of oxytocin receptor gene polymorphism and depression on hippocampal volume. Psychiatry Research - Neuroimaging, 2018, 282, 18-23.	1.8	19
74	Whole-exome sequencing identifies variants associated with structural MRI markers in patients with bipolar disorders. Journal of Affective Disorders, 2019, 249, 159-168.	4.1	19
75	Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opinion on Investigational Drugs, 2017, 26, 687-698.	4.1	18
76	Association between weekend catch-up sleep and high-sensitivity C-reactive protein levels in adults: a population-based study. Sleep, 2020, 43, .	1.1	17
77	Do We Need to Consider Ethno-cultural Variation in the Use of Atypical Antipsychotics for Asian Patients with Major Depressive Disorder?. CNS Drugs, 2013, 27, 47-51.	5.9	16
78	Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam Medical Journal, 2015, 51, 66.	0.9	16
79	Increase in the prescription rate of antidepressants after the Sewol Ferry disaster in Ansan, South Korea. Journal of Affective Disorders, 2017, 219, 31-36.	4.1	16
80	Depression and Cognitive Function in Mild Cognitive Impairment: A 1-Year Follow-Up Study. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 280-288.	2.3	16
81	Efficacy of antidepressants: bias in randomized clinical trials and related issues. Expert Review of Clinical Pharmacology, 2018, 11, 15-25.	3.1	16
82	Long working hours and depressive symptoms: moderation by gender, income, and job status. Journal of Affective Disorders, 2021, 286, 99-107.	4.1	16
83	CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investigation, 2013, 10, 286.	1.6	16
84	Association of Depression With Atrial Fibrillation in South Korean Adults. JAMA Network Open, 2022, 5, e2141772.	5.9	16
85	Diagnosis and treatment of dementia in primary care. Journal of the Korean Medical Association, 2013, 56, 1104.	0.3	15
86	Influence of Bcl I C/G (rs41423247) on hippocampal shape and white matter integrity of the parahippocampal cingulum in major depressive disorder. Psychoneuroendocrinology, 2016, 72, 147-155.	2.7	15
87	Precision medicine for psychopharmacology: a general introduction. Expert Review of Neurotherapeutics, 2016, 16, 831-839.	2.8	15
88	The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. Advances in Therapy, 2017, 34, 713-724.	2.9	15
89	Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study. Clinical Psychopharmacology and Neuroscience, 2017, 15, 28-34.	2.0	15
90	Increased plasma complement factor H is associated with geriatric depression. International Psychogeriatrics, 2019, 31, 101-108.	1.0	15

#	Article	IF	CITATIONS
91	Pathways to care for people with dementia: An international multicentre study. International Journal of Geriatric Psychiatry, 2020, 35, 163-173.	2.7	15
92	Standardization of the Korean Version of the Patient Health Questionnaire-4 (PHQ-4). Clinical Psychopharmacology and Neuroscience, 2021, 19, 104-111.	2.0	15
93	Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: A randomized, open-label, 12-week, parallel-group trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 437-444.	4.8	14
94	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. Advances in Therapy, 2018, 35, 1656-1670.	2.9	14
95	Cerebral amyloid accumulation is associated with distinct structural and functional alterations in the brain of depressed elders with mild cognitive impairment. Journal of Affective Disorders, 2021, 281, 459-466.	4.1	14
96	Depression, suicide, and Korean society. Journal of the Korean Medical Association, 2011, 54, 358.	0.3	13
97	Uptake of Web-Based Clinical Resources from the MacArthur Initiative on Depression and Primary Care. Community Mental Health Journal, 2013, 49, 166-171.	2.0	13
98	Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition. Journal of Korean Medical Science, 2014, 29, 468.	2.5	13
99	Vesicular monoamine transporter 1 gene polymorphism and white matter integrity in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 138-145.	4.8	13
100	Alterations in the brainstem volume of patients with major depressive disorder and their relationship with antidepressant treatment. Journal of Affective Disorders, 2017, 208, 68-75.	4.1	13
101	Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder. Psychiatry Investigation, 2014, 11, 481.	1.6	13
102	Psychiatric Symptoms in a Patient with Influenza A (H1N1) Treated with Oseltamivir (Tamiflu): A Case Report. Clinical Psychopharmacology and Neuroscience, 2015, 13, 209-211.	2.0	13
103	Possible association between G-protein $\hat{I}^2$ 3 subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia. Acta Neuropsychiatrica, 2007, 19, 351-356.	2.1	12
104	Management of Chronic Depressive Patients with Residual Symptoms. CNS Drugs, 2013, 27, 53-57.	5.9	12
105	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. Journal of Affective Disorders, 2019, 249, 410-417.	4.1	12
106	Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2020, 87, 103995.	3.0	12
107	Volumetric alterations in subregions of the amygdala in adults with major depressive disorder. Journal of Affective Disorders, 2021, 295, 108-115.	4.1	12
108	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for <i>CACNA1C, CHRNA7</i> and <i>MAPK1</i> . Clinical Psychopharmacology and Neuroscience, 2019, 17, 364-368.	2.0	12

#	Article	lF	Citations
109	The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study. Clinical Psychopharmacology and Neuroscience, 2019, 17, 495-502.	2.0	12
110	Association between work-family conflict and depressive symptoms in female workers: An exploration of potential moderators. Journal of Psychiatric Research, 2022, 151, 113-121.	3.1	12
111	Posttraumatic Growth and Resilience: Assessment and Clinical Implications. Journal of Korean Neuropsychiatric Association, 2015, 54, 32.	0.5	11
112	The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia. International Journal of Molecular Sciences, 2015, 16, 2517-2529.	4.1	11
113	The association between substance P and white matter integrity in medication-naive patients with major depressive disorder. Scientific Reports, 2017, 7, 9707.	3.3	11
114	Intimate partner violence and incidence of depression in married women: A longitudinal study of a nationally representative sample. Journal of Affective Disorders, 2019, 245, 305-311.	4.1	11
115	Can botulinum toxin improve mood in depressed patients?. Expert Review of Neurotherapeutics, 2012, 12, 1049-1051.	2.8	10
116	Association between brain amyloid accumulation and neuropsychological characteristics in elders with depression and mild cognitive impairment. International Journal of Geriatric Psychiatry, 2019, 34, 1907-1915.	2.7	10
117	Association of metabolic syndrome and its components with suicidal ideation and depression in adults: A nationally representative sample of the Korean population. Journal of Affective Disorders, 2019, 249, 319-326.	4.1	10
118	A study combining whole-exome sequencing and structural neuroimaging analysis for major depressive disorder. Journal of Affective Disorders, 2020, 262, 31-39.	4.1	10
119	Association between high-sensitivity C-reactive protein levels and depression: Moderation by age, sex, obesity, and aerobic physical activity. Journal of Affective Disorders, 2021, 291, 375-383.	4.1	10
120	A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders. PLoS ONE, 2017, 12, e0179247.	2.5	10
121	Alterations in the Occipital Cortex of Drug-NaÃ-ve Adults With Major Depressive Disorder: A Surface-Based Analysis of Surface Area and Cortical Thickness. Psychiatry Investigation, 2021, 18, 1025-1033.	1.6	10
122	Development of an International Schedule for the Assessment and Staging of Care for Dementia. Journal of Alzheimer's Disease, 2015, 44, 139-151.	2.6	9
123	Decreased cortical gyrification in patients with bipolar disorder. Psychological Medicine, 2022, 52, 2232-2244.	4.5	9
124	Comparison of shape alterations of the thalamus and caudate nucleus between drug-na $\tilde{A}$ -ve major depressive disorder patients and healthy controls. Journal of Affective Disorders, 2020, 264, 279-285.	4.1	9
125	Association of Prefrontal Cortex Thinning with High Impulsivity in Healthy Adults. Psychiatry Investigation, 2021, 18, 570-579.	1.6	9
126	A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises. Psychiatry Investigation, 2014, 11, 371.	1.6	9

#	Article	IF	CITATIONS
127	Sleep Irregularity in the Previous Week Influences the First-Night Effect in Polysomnographic Studies. Psychiatry Investigation, 2016, 13, 203.	1.6	9
128	Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical Psychopharmacology and Neuroscience, 2020, 18, 153-158.	2.0	9
129	The relationship between somatic symptoms and depression. Neuroendocrinology Letters, 2014, 35, 463-9.	0.2	9
130	Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial. Acta Neuropsychiatrica, 2011, 23, 179-183.	2.1	8
131	Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. Neuropsychiatric Disease and Treatment, 2014, 10, 1605.	2.2	8
132	Eye Movement Desensitization and Reprocessing to Facilitate Posttraumatic Growth: A Prospective Clinical Pilot Study on Ferry Disaster Survivors. Clinical Psychopharmacology and Neuroscience, 2017, 15, 320-327.	2.0	8
133	Effect of physical activity on suicidal ideation differs by gender and activity level. Journal of Affective Disorders, 2019, 257, 116-122.	4.1	8
134	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 901-910.	3.2	8
135	Development of Neuroimaging-Based Biomarkers in Major Depression. Advances in Experimental Medicine and Biology, 2021, 1305, 85-99.	1.6	8
136	Gender discrimination in workplace and depressive symptoms in female employees in South Korea. Journal of Affective Disorders, 2022, 306, 269-275.	4.1	8
137	The impact of 3D and 2D TV watching on neurophysiological responses and cognitive functioning in adults. European Journal of Public Health, 2015, 25, 1047-1052.	0.3	7
138	Local shape volume alterations in subcortical structures of suicide attempters with major depressive disorder. Human Brain Mapping, 2020, 41, 4925-4934.	3.6	7
139	<p>Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2929-2941.	2.2	7
140	Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?. Clinical Psychopharmacology and Neuroscience, 2021, 19, 434-448.	2.0	7
141	Cortical Thickness and Surface Area Abnormalities in Bipolar I and II Disorders. Psychiatry Investigation, 2021, 18, 850-863.	1.6	6
142	Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2021, 19, 600-609.	2.0	6
143	Cognitive performance norms from the Korean genome and epidemiology study (KoGES). International Psychogeriatrics, 2017, 29, 1909-1924.	1.0	5
144	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. Journal of Molecular Neuroscience, 2018, 64, 273-286.	2.3	5

#	Article	IF	Citations
145	How to approach to suicide prevention. Journal of the Korean Medical Association, 2019, 62, 79.	0.3	5
146	<p>Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2943-2959.	2.2	5
147	Prospective study on microstructure in medication-na $\tilde{A}$ ve adolescents with first-episode major depressive disorder. Journal of Affective Disorders, 2021, 293, 268-275.	4.1	5
148	Comorbid Zolpidem Dependence and Over-the-Counter Compound Analgesic Abuse. Clinical Psychopharmacology and Neuroscience, 2019, 17, 323-325.	2.0	5
149	<i>ZNF804A</i> Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. Clinical Psychopharmacology and Neuroscience, 2020, 18, 231-240.	2.0	5
150	Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study. Psychiatry Investigation, 2022, 19, 268-280.	1.6	5
151	Oral scopolamine augmentation for major depression. Expert Review of Neurotherapeutics, 2013, 13, 19-21.	2.8	4
152	Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder. Clinical Psychopharmacology and Neuroscience, 2021, 19, 243-253.	2.0	4
153	Natural Course of Posttraumatic Symptoms in Late-Adolescent Maritime Disaster Survivors: Results of A 12-Month Follow-Up Study. Psychiatry Investigation, 2018, 15, 574-583.	1.6	4
154	Emotional Changes and Protective Factors of Emotional Workers in the Public and Private Sector. Psychiatry Investigation, 2020, 17, 645-653.	1.6	4
155	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (I): Initial Choice of Antidepressant Treatment. Journal of Korean Neuropsychiatric Association, 2013, 52, 253.	0.5	4
156	Association of DNA Methylation of the NLRP3 Gene with Changes in Cortical Thickness in Major Depressive Disorder. International Journal of Molecular Sciences, 2022, 23, 5768.	4.1	4
157	Dilemma for enhancing psychiatrists' adherence to guideline (evidence)-based practice. Expert Review of Neurotherapeutics, 2013, 13, 751-754.	2.8	3
158	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Advances in Therapy, 2017, 34, 1482-1497.	2.9	3
159	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. Journal of Molecular Neuroscience, 2018, 64, 62-74.	2.3	3
160	Promising neural diagnostic biomarkers and predictors of treatment outcomes for psychiatric disorders: Novel neuroimaging approaches. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 1-3.	4.8	3
161	Changes in cortical thickness and volume of cerebellar subregions in patients with bipolar disorders. Journal of Affective Disorders, 2020, 271, 74-80.	4.1	3
162	The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer's Dementia: A Double-Blind Randomized Placebo-Controlled Trial. Psychiatry Investigation, 2021, 18, 233-240.	1.6	3

#	Article	IF	Citations
163	Big Data and Discovery Sciences in Psychiatry. Advances in Experimental Medicine and Biology, 2019, 1192, 3-15.	1.6	3
164	The Development of Evidence-Based Guideline for Diagnosis and Management of Headache in Korea. Psychiatry Investigation, 2019, 16, 199-205.	1.6	3
165	The Indirect Effect of Prefrontal Gray Matter Volume on Suicide Attempts among Individuals with Major Depressive Disorder. Experimental Neurobiology, 2022, 31, 97-104.	1.6	3
166	Sickness absence indicating depressive symptoms of working population in South Korea. Journal of Affective Disorders, 2018, 227, 443-449.	4.1	2
167	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. Clinical Psychopharmacology and Neuroscience, 2021, 19, 46-52.	2.0	2
168	Changes in Brain Electrical Activity According to Post-traumatic Stress Symptoms in Survivors of the Sewol Ferry Disaster: A 1-year Longitudinal Study. Clinical Psychopharmacology and Neuroscience, 2021, 19, 537-544.	2.0	2
169	Brain amyloid accumulation possibly exacerbates concurrent mild cognitive impairment with subthreshold depression in older adults: A 1-year follow-up study. Journal of Affective Disorders, 2021, 295, 93-100.	4.1	2
170	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (III): Dose Increment, Switching, Combination, and Augmentation Strategy in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association, 2013, 52, 386.	0.5	2
171	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (II): Antidepressant Efficacy Compared with Placebo, Difference in Efficacy of Antidepressants, and Appropriate Time of Efficacy Judgment in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association, 2013, 52, 372.	0.5	2
172	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. Psychiatry Investigation, 2014, 11, 200.	1.6	2
173	The associations of TAC1 gene polymorphisms with major depressive disorder. Molecular and Cellular Toxicology, 2019, 15, 129-136.	1.7	1
174	Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical Psychopharmacology and Neuroscience, 2021, 19, 233-242.	2.0	1
175	The neural circuit model of depression and the therapeutic mechanism of cognitive behavioral therapy: A review of functional brain magnetic resonance imaging studies. Cognitive Behavior Therapy in Korea, 2021, 21, 665-688.	0.1	1
176	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clinical Psychopharmacology and Neuroscience, 2018, 16, 469-480.	2.0	1
177	Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study. Current Therapeutic Research, 2008, 69, 221-231.	1.2	0
178	Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease. Expert Review of Neurotherapeutics, 2012, 12, 155-158.	2.8	0
179	PS227. Psychometric Properties of the Korean Version of the Clinically Useful Depression Outcome Scale (CUDOS) in Psychiatric Outpatients. International Journal of Neuropsychopharmacology, 2016, 19, 83-83.	2.1	0
180	PM449. Hot genes in schizophrenia: case-control, pharmacogenetics and exploratory analyses in two independent samples. International Journal of Neuropsychopharmacology, 2016, 19, 63-63.	2.1	0

#	Article	IF	CITATIONS
181	Diagnostic and Therapeutic Model for Korean Major Depressive Disorder Using Multi-Modal Data. Journal of KIISE, 2019, 46, 71-76.	0.1	O
182	Comparison of Morning and Evening/Night Dosing on the Efficacy of Escitalopram in Major Depressive Disorder at Naturalistic Setting. Chronobiology in Medicine, 2019, 1, 152-156.	0.4	0
183	Geriatric mental health system for the management of geriatric depression and dementia in Korea. Psychiatria Et Neurologia Japonica - Seishin Shinkeigaku Zasshi, 2006, 108, 1176-7.	0.1	O
184	Pharmacotherapy for late-life depression. Journal of the Korean Medical Association, 2022, 65, 176-184.	0.3	0
185	Associations between cognitive impairment and cortical thickness alterations in patients with euthymic and depressive bipolar disorder. Psychiatry Research - Neuroimaging, 2022, 322, 111462.	1.8	0